C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 403/12 (2006.01) A61K 31/4015 (2006.01) A61K 31/41 (2006.01) C07D 207/26 (2006.01)
Patent
CA 2466751
This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
L'invention concerne des agonistes sélectifs puissants du sous-type EP¿4? des récepteurs de la prostaglandine E2, l'utilisation de ceux-ci ou une formulation de ceux-ci dans le traitement du glaucome et d'autres états relatifs à une pression intraoculaire élevée dans l'oeil d'un patient. L'invention concerne également l'utilisation des composés selon l'invention pour induire le remodelage des os et remodeler des processus des ostéoblastes et ostéoclastes.
Billot Xavier
Metters Kathleen M.
Ogidigben Miller J.
Slipetz Deborah M.
Young Robert N.
Merck And Co. Inc.
Merck Frosst Canada & Co./merck Frosst Canada & Cie
Merck Frosst Canada Ltd.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Ep4 receptor agonist, compositions and methods thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ep4 receptor agonist, compositions and methods thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ep4 receptor agonist, compositions and methods thereof will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1851355